Author + information
- Anis Alyavi,
- Umida Kamilova,
- Dildora Tulyaganova,
- Nasima Kayumova,
- Dyora Rajabova and
- Bekzod Toshev
To study clinical efficacy of Tivortin (L-arginine) on hemodynamic parameters in patients with coronary heart disease (CHD) after coronary artery stenting.
The study involved 55 patients with coronary heart disease: stable angina FC II-III. All patients underwent myocardial revascularization through balloon angioplasty with stenting of coronary arteries. Depending on the method of treatment, patients were divided into two groups. Patients of group I (n = 33) received Tivortin 100 ml 1 time per day during 10 days, patients of group II (n = 22) received standard therapy.
The treatment of the average heart rate (HR) in both groups decreased significantly. In group II HR decreased by 21.5%, whereas in group of patients, who treated with additional Tivortin HR decreased by 12 beats per 1 min (26.8%) (p < 0.001). Also significantly reduced the average parameters of systolic blood pressure (SBP) and diastolic blood pressure (DBP) in both study groups, which almost reached the target levels. Thus, in patients treated with standard therapy SBP decreased from 163, 4 ± 5, 1 to 132, 5 ± 3,6 mm Hg (p <0.05), whereas in patients treated with additional Tivortin SBP decreased from 161.4 ± 5.17 to 131, 0 ± 4,7 mm Hg (p <0.05). In the study of central hemodynamics marked improvement in contractility of the left ventricle. For inclusion in the treatment Tivortin contributed to an increase in ejection fraction (EF) of 9.1% (p <0.05), whereas in patients treated with standard therapy, EF increased by 1.5% (p> 0.05). It was revealed that end-diastolic index, which was lower in patients than in healthy controls (p <0.05), with no significant difference between the groups, under the influence of treatment increased slightly.
Tivortin inclusion in complex therapy of patients with IHD with stable angina FC II-III, undergoing coronary artery stenting, resulting in significant improvement in hemodynamic parameters.